| # | Title | Journal | Year | Citations |
|---|
| 1 | Landscape of somatic mutations in 560 breast cancer whole-genome sequences | Nature | 2016 | 1,760 |
| 2 | The landscape of cancer genes and mutational processes in breast cancer | Nature | 2012 | 1,535 |
| 3 | Large-scale genotyping identifies 41 new loci associated with breast cancer risk | Nature Genetics | 2013 | 960 |
| 4 | Breast Cancer after Prophylactic Bilateral Mastectomy in Women with aBRCA1orBRCA2Mutation | New England Journal of Medicine | 2001 | 910 |
| 5 | Complex landscapes of somatic rearrangement in human breast cancer genomes | Nature | 2009 | 776 |
| 6 | HRDetect is a predictor of BRCA1 and BRCA2 deficiency based on mutational signatures | Nature Medicine | 2017 | 769 |
| 7 | Subtypes of Breast Cancer Show Preferential Site of Relapse | Cancer Research | 2008 | 674 |
| 8 | Genome-wide association study identifies five new breast cancer susceptibility loci | Nature Genetics | 2010 | 653 |
| 9 | Pazopanib, a Multikinase Angiogenesis Inhibitor, in Patients With Relapsed or Refractory Advanced Soft Tissue Sarcoma: A Phase II Study From the European Organisation for Research and Treatment of Cancer–Soft Tissue and Bone Sarcoma Group (EORTC Study 62043) | Journal of Clinical Oncology | 2009 | 611 |
| 10 | Parent-of-origin-specific allelic associations among 106 genomic loci for age at menarche | Nature | 2014 | 548 |
| 11 | Genomic Evolution of Breast Cancer Metastasis and Relapse | Cancer Cell | 2017 | 534 |
| 12 | CCAT2, a novel noncoding RNA mapping to 8q24, underlies metastatic progression and chromosomal instability in colon cancer | Genome Research | 2013 | 526 |
| 13 | Multiple independent variants at the TERT locus are associated with telomere length and risks of breast and ovarian cancer | Nature Genetics | 2013 | 493 |
| 14 | European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer: A Report of the Second Meeting of the European Germ Cell Cancer Consensus group (EGCCCG): Part I | European Urology | 2008 | 488 |
| 15 | Use of c-KIT/PDGFRA mutational analysis to predict the clinical response to imatinib in patients with advanced gastrointestinal stromal tumours entered on phase I and II studies of the EORTC Soft Tissue and Bone Sarcoma Group | European Journal of Cancer | 2004 | 435 |
| 16 | Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2 | Nature Genetics | 2009 | 434 |
| 17 | Association of Type and Location ofBRCA1andBRCA2Mutations With Risk of Breast and Ovarian Cancer | JAMA - Journal of the American Medical Association | 2015 | 390 |
| 18 | Selection of Bone Metastasis Seeds by Mesenchymal Signals in the Primary Tumor Stroma | Cell | 2013 | 359 |
| 19 | Large-scale genomic analyses link reproductive aging to hypothalamic signaling, breast cancer susceptibility and BRCA1-mediated DNA repair | Nature Genetics | 2015 | 357 |
| 20 | Identification of 12 new susceptibility loci for different histotypes of epithelial ovarian cancer | Nature Genetics | 2017 | 356 |
| 21 | Extensive transduction of nonrepetitive DNA mediated by L1 retrotransposition in cancer genomes | Science | 2014 | 348 |
| 22 | The role of microRNAs in cancer: No small matter | European Journal of Cancer | 2007 | 318 |
| 23 | Heterogeneity of Breast Cancer Associations with Five Susceptibility Loci by Clinical and Pathological Characteristics | PLoS Genetics | 2008 | 315 |
| 24 | The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; A review | European Journal of Cancer | 2006 | 314 |
| 25 | A locus on 19p13 modifies risk of breast cancer in BRCA1 mutation carriers and is associated with hormone receptor–negative breast cancer in the general population | Nature Genetics | 2010 | 309 |
| 26 | Phosphatidylinositol-3-OH Kinase or RAS Pathway Mutations in Human Breast Cancer Cell Lines | Molecular Cancer Research | 2007 | 271 |
| 27 | Pan-cancer landscape of homologous recombination deficiency | Nature Communications | 2020 | 262 |
| 28 | Genome-wide association analysis identifies three new breast cancer susceptibility loci | Nature Genetics | 2012 | 256 |
| 29 | The genomic landscape of metastatic breast cancer highlights changes in mutation and signature frequencies | Nature Genetics | 2019 | 250 |
| 30 | Distinct gene mutation profiles among luminal-type and basal-type breast cancer cell lines | Breast Cancer Research and Treatment | 2010 | 247 |
| 31 | Genome-Wide Association Study in BRCA1 Mutation Carriers Identifies Novel Loci Associated with Breast and Ovarian Cancer Risk | PLoS Genetics | 2013 | 244 |
| 32 | DPYD genotype-guided dose individualisation of fluoropyrimidine therapy in patients with cancer: a prospective safety analysis | Lancet Oncology, The | 2018 | 238 |
| 33 | BRCA1 Mutation Analysis of 41 Human Breast Cancer Cell Lines Reveals Three New Deleterious Mutants | Cancer Research | 2006 | 237 |
| 34 | Vascular disrupting agents in clinical development | British Journal of Cancer | 2007 | 237 |
| 35 | The topography of mutational processes in breast cancer genomes | Nature Communications | 2016 | 235 |
| 36 | Oncological management and obstetric and neonatal outcomes for women diagnosed with cancer during pregnancy: a 20-year international cohort study of 1170 patients | Lancet Oncology, The | 2018 | 235 |
| 37 | Targeted sequencing by proximity ligation for comprehensive variant detection and local haplotyping | Nature Biotechnology | 2014 | 231 |
| 38 | Somatic mutations reveal asymmetric cellular dynamics in the early human embryo | Nature | 2017 | 229 |
| 39 | Side Effects of Interferon-α Therapy | International Journal of Clinical Pharmacy | 2005 | 228 |
| 40 | Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas | European Journal of Cancer | 2010 | 224 |
| 41 | A phase I dose escalation study of BIBW 2992, an irreversible dual inhibitor of epidermal growth factor receptor 1 (EGFR) and 2 (HER2) tyrosine kinase in a 2-week on, 2-week off schedule in patients with advanced solid tumours | British Journal of Cancer | 2008 | 217 |
| 42 | A systematic review on barriers hindering adequate cancer pain management and interventions to reduce them: A critical appraisal | European Journal of Cancer | 2009 | 217 |
| 43 | The mutational footprints of cancer therapies | Nature Genetics | 2019 | 212 |
| 44 | Detection of residual disease after neoadjuvant chemoradiotherapy for oesophageal cancer (preSANO): a prospective multicentre, diagnostic cohort study | Lancet Oncology, The | 2018 | 211 |
| 45 | Prevalence of potential drug–drug interactions in cancer patients treated with oral anticancer drugs | British Journal of Cancer | 2013 | 196 |
| 46 | Angiogenesis inhibitors in clinical development; where are we now and where are we going? | British Journal of Cancer | 2004 | 185 |
| 47 | Alternative drug formulations of docetaxel: a review | Anti-Cancer Drugs | 2007 | 181 |
| 48 | The Systemic-immune-inflammation Index Independently Predicts Survival and Recurrence in Resectable Pancreatic Cancer and its Prognostic Value Depends on Bilirubin Levels | Annals of Surgery | 2019 | 179 |
| 49 | Cause-specific mortality in long-term survivors of breast cancer: A 25-year follow-up study | International Journal of Radiation Oncology Biology Physics | 2006 | 178 |
| 50 | Molecular characterization of circulating tumor cells in large quantities of contaminating leukocytes by a multiplex real-time PCR | Breast Cancer Research and Treatment | 2009 | 171 |
